JP2016522261A5 - - Google Patents

Download PDF

Info

Publication number
JP2016522261A5
JP2016522261A5 JP2016521553A JP2016521553A JP2016522261A5 JP 2016522261 A5 JP2016522261 A5 JP 2016522261A5 JP 2016521553 A JP2016521553 A JP 2016521553A JP 2016521553 A JP2016521553 A JP 2016521553A JP 2016522261 A5 JP2016522261 A5 JP 2016522261A5
Authority
JP
Japan
Prior art keywords
agent
therapeutic
patient
kit
solid support
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016521553A
Other languages
English (en)
Japanese (ja)
Other versions
JP6622192B2 (ja
JP2016522261A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/043020 external-priority patent/WO2014205126A1/en
Publication of JP2016522261A publication Critical patent/JP2016522261A/ja
Publication of JP2016522261A5 publication Critical patent/JP2016522261A5/ja
Application granted granted Critical
Publication of JP6622192B2 publication Critical patent/JP6622192B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016521553A 2013-06-19 2014-06-18 治療薬を局所的送達するための化学構造 Active JP6622192B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361836800P 2013-06-19 2013-06-19
US61/836,800 2013-06-19
PCT/US2014/043020 WO2014205126A1 (en) 2013-06-19 2014-06-18 Chemical structures for localized delivery of therapeutic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019009039A Division JP2019089794A (ja) 2013-06-19 2019-01-23 治療薬を局所的送達するための化学構造

Publications (3)

Publication Number Publication Date
JP2016522261A JP2016522261A (ja) 2016-07-28
JP2016522261A5 true JP2016522261A5 (enExample) 2017-07-27
JP6622192B2 JP6622192B2 (ja) 2019-12-18

Family

ID=52105244

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016521553A Active JP6622192B2 (ja) 2013-06-19 2014-06-18 治療薬を局所的送達するための化学構造
JP2019009039A Withdrawn JP2019089794A (ja) 2013-06-19 2019-01-23 治療薬を局所的送達するための化学構造

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019009039A Withdrawn JP2019089794A (ja) 2013-06-19 2019-01-23 治療薬を局所的送達するための化学構造

Country Status (6)

Country Link
US (2) US10130711B2 (enExample)
EP (1) EP3010486B1 (enExample)
JP (2) JP6622192B2 (enExample)
CN (1) CN105611914B (enExample)
ES (1) ES2966631T3 (enExample)
WO (1) WO2014205126A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
ES2966631T3 (es) 2013-06-19 2024-04-23 Univ California Estructuras químicas para el suministro localizado de agentes terapéuticos
CN106659796B (zh) 2014-03-14 2021-04-30 加利福尼亚大学董事会 Tco缀合物和治疗剂递送方法
US20170119892A1 (en) * 2014-04-04 2017-05-04 President And Fellows Of Harvard College Refillable drug delivery devices and methods of use thereof
WO2017044983A1 (en) * 2015-09-10 2017-03-16 Shasqi, Inc. Bioorthogonal compositions
EP3153155B1 (en) * 2015-10-08 2021-03-03 President and Fellows of Harvard College Refillable drug delivery devices and methods of use thereof
KR102228571B1 (ko) * 2017-02-09 2021-03-16 주식회사 메디폴리머 정신질환 또는 중추신경계 질환 치료용 약물전달 제형
AU2018250312C1 (en) 2017-04-07 2024-08-22 Tambo, Inc. Bioorthogonal compositions
US11560384B2 (en) 2017-05-04 2023-01-24 University Of Utah Research Foundation Benzonorbornadiene derivatives and reactions thereof
SG11202103393XA (en) 2018-10-10 2021-04-29 Tambo Inc Processes for preparing functionalized cyclooctenes
WO2021007160A1 (en) 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
CN116056765A (zh) 2020-08-07 2023-05-02 坦伯公司 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途
EP4108669A1 (en) * 2021-06-24 2022-12-28 Institute Of Organic Chemistry And Biochemistry As CR, V.V.I. Carbohydrate derivatives and kits for cell surface labeling
WO2023077129A1 (en) 2021-10-29 2023-05-04 Tambo, Inc. Tetrazine conjugates for in vivo targeted delivery of a payload
EP4422693A1 (en) 2021-10-29 2024-09-04 Tambo, Inc. Trans-cyclooctene conjugates
US20250009890A1 (en) 2021-11-05 2025-01-09 Tambo, Inc. Trans-cyclooctene-modified bispecific antibodies
WO2024168065A1 (en) 2023-02-08 2024-08-15 Tambo, Inc. System comprising modified whole cell payloads for targeted delivery
WO2024178155A1 (en) 2023-02-21 2024-08-29 Tambo, Inc. Trans-cyclooctene conjugates
CN121419788A (zh) 2023-05-04 2026-01-27 坦博公司 用于体内递送有效载荷的基于四嗪的靶向剂
EP4713022A1 (en) 2023-05-18 2026-03-25 Tambo, Inc. Trans-cyclooctene-modified targeted protein degrader conjugates
WO2025059685A1 (en) 2023-09-15 2025-03-20 Tambo, Inc. Methods for in vivo targeted delivery of a payload

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658592A (en) * 1994-05-13 1997-08-19 Kuraray Co., Ltd. Medical crosslinked polymer gel of carboxylic polysaccharide and diaminoalkane
AU2002315414B2 (en) 2001-06-21 2008-02-07 Clontech Laboratories, Inc. Water-soluble polymeric metal ion affinity compositions and methods for using the same
JPWO2003084571A1 (ja) * 2002-04-08 2005-08-11 電気化学工業株式会社 骨感染症治療用組成物
US7445894B2 (en) 2002-05-03 2008-11-04 Molecular Probes, Inc. Compositions and methods for detection and isolation of phosphorylated molecules
EP1534269B1 (en) 2002-07-19 2013-10-30 The General Hospital Corporation Oxime conjugates and methods for their formation and use
US7968085B2 (en) * 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
RU2396985C2 (ru) * 2004-08-03 2010-08-20 Тиссьюмед Лимитед Материалы, обладающие адгезией к тканям
US20090304587A1 (en) * 2005-11-01 2009-12-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Biodegradable composite for internal local radiotherapy
EP1867638A1 (de) 2006-06-16 2007-12-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verfahren zur kovalenten Verknüpfung zweier Moleküle mittels Diels-Alder-Reaktion mit inversem Elektronenbedarf
US8398956B2 (en) 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
US8236949B2 (en) 2007-07-17 2012-08-07 University Of Delaware Tetrazine-based bio-orthogonal coupling reagents and methods
WO2011127149A1 (en) 2010-04-06 2011-10-13 University Of Utah Research Foundation Controlled release combination biomaterials
JP5574083B2 (ja) * 2008-08-01 2014-08-20 アンタイス エス.エイ. 高い残留性及び容量を与える高い能力を有する注入可能なヒドロゲル
AU2009282413B2 (en) 2008-08-11 2014-07-17 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
US8900549B2 (en) 2008-10-31 2014-12-02 The General Hospital Corporation Compositions and methods for delivering a substance to a biological target
TW201021852A (en) 2008-11-17 2010-06-16 Enzon Pharmaceuticals Inc Releasable fusogenic lipids for nucleic acids delivery systems
WO2010096654A1 (en) * 2009-02-21 2010-08-26 Tyco Healthcare Group Lp Medical devices having activated surfaces
CN102395380B (zh) 2009-04-16 2015-05-20 皇家飞利浦电子股份有限公司 预靶向试剂盒、方法和其中使用的试剂
CA2769162C (en) 2009-07-31 2017-12-05 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
EP2566334B1 (en) 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
US10434197B2 (en) 2010-07-23 2019-10-08 University Of Delaware Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes
US9463256B2 (en) 2010-10-14 2016-10-11 Koninklijke Philips N.V. Pretargeting kit, method and agents used therein
WO2012074840A2 (en) 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
JP5992435B2 (ja) 2010-12-21 2016-09-14 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. 循環からの生体分子の除去剤
EP2522369A1 (en) * 2011-05-09 2012-11-14 Koninklijke Philips Electronics N.V. Pretargeting kit, method and agents used therein
CA2836338C (en) 2011-05-16 2022-05-03 Koninklijke Philips N.V. Tetrazine derivatives used in bio-orthogonal drug activation
EP2716662A4 (en) * 2011-05-31 2014-11-19 Univ Tokyo HYDROGEL AND METHOD FOR ITS MANUFACTURE
ES2393602B1 (es) 2011-06-09 2013-10-02 Universidad Complutense De Madrid Materiales biocerámicos para el tratamiento de la osteomielitis.
US9206271B2 (en) 2012-03-25 2015-12-08 Wisconsin Alumni Research Foundation Fully backbone degradable and functionalizable polymers derived from the ring-opening metathesis polymerization (ROMP)
WO2013187954A1 (en) 2012-06-12 2013-12-19 The General Hospital Corporation Magnetic labeling of bacteria
WO2014004278A1 (en) * 2012-06-26 2014-01-03 The Curators Of The University Of Missouri Photocleavable drug conjugates
WO2014065860A1 (en) 2012-10-24 2014-05-01 The General Hospital Corporation Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
WO2014081300A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Channel protein activatable liposomes
US20150297741A1 (en) 2012-11-22 2015-10-22 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
FI2922574T3 (fi) 2012-11-22 2023-08-11 Tagworks Pharmaceuticals B V Kemiallisesti pilkkoutuva ryhmä
WO2014081299A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Activatable liposomes
US20150359913A1 (en) 2013-01-25 2015-12-17 Memorial Sloan-Kettering Cancer Center Tetrazines/trans-cyclooctenes in solid phase synthesis of labeled peptides
WO2014138186A1 (en) 2013-03-05 2014-09-12 The Johns Hopkins University Bioorthogonal two-component delivery systems for enhanced internalization of nanotherapeutics
ES2754177T3 (es) 2013-06-12 2020-04-16 Massachusetts Gen Hospital Métodos para la detección multiplexada de moléculas diana y sus usos
ES2966631T3 (es) * 2013-06-19 2024-04-23 Univ California Estructuras químicas para el suministro localizado de agentes terapéuticos
CN106659796B (zh) 2014-03-14 2021-04-30 加利福尼亚大学董事会 Tco缀合物和治疗剂递送方法
US20170119892A1 (en) 2014-04-04 2017-05-04 President And Fellows Of Harvard College Refillable drug delivery devices and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2016522261A5 (enExample)
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
JP2008502584A5 (enExample)
WO2016077840A3 (en) Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use
NZ602824A (en) Sparc binding peptides and uses thereof
JP2013518912A5 (enExample)
MX2019013701A (es) Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos.
JP2010505850A5 (enExample)
WO2016004048A3 (en) Targeted conjugates and particles and formulations thereof
JP2011507933A5 (enExample)
WO2010046900A3 (en) Rgd-containing peptidomimetics and uses thereof
JP2010507432A5 (enExample)
EP2211913A4 (en) SYSTEMIC ADMINISTRATION OF CHLOROTOXIN AGENTS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
JP2016513640A5 (enExample)
UA98136C2 (ru) Применение аклидиния для лечения респираторных заболеваний
EP2949344A3 (en) Use of intracellular enzymes for the release of covalently linked bioactives
WO2010065950A3 (en) Albumin binding peptide-mediated disease targeting
JP2009525348A5 (enExample)
JP2005535606A5 (enExample)
Lozano et al. Nanomedicine for the cardiac myocyte: where are we?
WO2008136869A3 (en) Methods and compositions related to targeting wounds, regenerating tissue, and tumors
EA032908B1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
WO2010093925A3 (en) Peripheral administration of proteins including tgf-beta superfamily members for systemic treatment of disorders and disease
WO2011002852A3 (en) Pro-drug complexes and related methods of use
JP2013510169A5 (enExample)